BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24075187)

  • 21. A proteomics study identifying interactors of the FSHD2 gene product SMCHD1 reveals RUVBL1-dependent DUX4 repression.
    Goossens R; Tihaya MS; van den Heuvel A; Tabot-Ndip K; Willemsen IM; Tapscott SJ; González-Prieto R; Chang JG; Vertegaal ACO; Balog J; van der Maarel SM
    Sci Rep; 2021 Dec; 11(1):23642. PubMed ID: 34880314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homozygous nonsense variant in
    Hamanaka K; Šikrová D; Mitsuhashi S; Masuda H; Sekiguchi Y; Sugiyama A; Shibuya K; Lemmers RJLF; Goossens R; Ogawa M; Nagao K; Obuse C; Noguchi S; Hayashi YK; Kuwabara S; Balog J; Nishino I; van der Maarel SM
    Neurology; 2020 Jun; 94(23):e2441-e2447. PubMed ID: 32467133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SMCHD1 regulates a limited set of gene clusters on autosomal chromosomes.
    Mason AG; Slieker RC; Balog J; Lemmers RJLF; Wong CJ; Yao Z; Lim JW; Filippova GN; Ne E; Tawil R; Heijmans BT; Tapscott SJ; van der Maarel SM
    Skelet Muscle; 2017 Jun; 7(1):12. PubMed ID: 28587678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.
    Mitsuhashi S; Boyden SE; Estrella EA; Jones TI; Rahimov F; Yu TW; Darras BT; Amato AA; Folkerth RD; Jones PL; Kunkel LM; Kang PB
    Neuromuscul Disord; 2013 Dec; 23(12):975-80. PubMed ID: 24128691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
    Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
    Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome.
    Renard D; Taieb G; Garibaldi M; Maues De Paula A; Bernard R; Lagha N; Cristofari G; Vovan C; Chaix C; Lévy N; Khau Van Kien P; Sacconi S
    Am J Med Genet A; 2018 Aug; 176(8):1760-1763. PubMed ID: 30055030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
    Haynes P; Bomsztyk K; Miller DG
    Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Facioscapulohumeral muscular dystrophy type 2].
    Sacconi S; Desnuelle C
    Rev Neurol (Paris); 2013; 169(8-9):564-72. PubMed ID: 23969240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical, muscle pathological, and genetic features of Japanese facioscapulohumeral muscular dystrophy 2 (FSHD2) patients with SMCHD1 mutations.
    Hamanaka K; Goto K; Arai M; Nagao K; Obuse C; Noguchi S; Hayashi YK; Mitsuhashi S; Nishino I
    Neuromuscul Disord; 2016; 26(4-5):300-8. PubMed ID: 27061275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facioscapulohumeral Muscular Dystrophy.
    Statland JM; Tawil R
    Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. PubMed ID: 27922500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain.
    Lemmers RJLF; van der Stoep N; Vliet PJV; Moore SA; San Leon Granado D; Johnson K; Topf A; Straub V; Evangelista T; Mozaffar T; Kimonis V; Shaw ND; Selvatici R; Ferlini A; Voermans N; van Engelen B; Sacconi S; Tawil R; Lamers M; van der Maarel SM
    J Med Genet; 2019 Oct; 56(10):693-700. PubMed ID: 31243061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Segregation between SMCHD1 mutation, D4Z4 hypomethylation and Facio-Scapulo-Humeral Dystrophy: a case report.
    Gaillard MC; Puppo F; Roche S; Dion C; Campana ES; Mariot V; Chaix C; Vovan C; Mazaleyrat K; Tasmadjian A; Bernard R; Dumonceaux J; Attarian S; Lévy N; Nguyen K; Magdinier F; Bartoli M
    BMC Med Genet; 2016 Sep; 17(1):66. PubMed ID: 27634379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.
    Greco A; Goossens R; van Engelen B; van der Maarel SM
    Clin Genet; 2020 Jun; 97(6):799-814. PubMed ID: 32086799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.
    Rieken A; Bossler AD; Mathews KD; Moore SA
    Neurology; 2021 Feb; 96(7):e1054-e1062. PubMed ID: 33443126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy in Patients Clinically Suspected of FSHD Using Optical Genome Mapping.
    Guruju NM; Jump V; Lemmers R; Van Der Maarel S; Liu R; Nallamilli BR; Shenoy S; Chaubey A; Koppikar P; Rose R; Khadilkar S; Hegde M
    Neurol Genet; 2023 Dec; 9(6):e200107. PubMed ID: 38021397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy.
    van den Boogaard ML; Lemmers RJLF; Balog J; Wohlgemuth M; Auranen M; Mitsuhashi S; van der Vliet PJ; Straasheijm KR; van den Akker RFP; Kriek M; Laurense-Bik MEY; Raz V; van Ostaijen-Ten Dam MM; Hansson KBM; van der Kooi EL; Kiuru-Enari S; Udd B; van Tol MJD; Nishino I; Tawil R; Tapscott SJ; van Engelen BGM; van der Maarel SM
    Am J Hum Genet; 2016 May; 98(5):1020-1029. PubMed ID: 27153398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.
    Hamel J; Tawil R
    Neurotherapeutics; 2018 Oct; 15(4):863-871. PubMed ID: 30361930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous measurement of the size and methylation of chromosome 4qA-D4Z4 repeats in facioscapulohumeral muscular dystrophy by long-read sequencing.
    Hiramuki Y; Kure Y; Saito Y; Ogawa M; Ishikawa K; Mori-Yoshimura M; Oya Y; Takahashi Y; Kim DS; Arai N; Mori C; Matsumura T; Hamano T; Nakamura K; Ikezoe K; Hayashi S; Goto Y; Noguchi S; Nishino I
    J Transl Med; 2022 Nov; 20(1):517. PubMed ID: 36348371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remotely acting SMCHD1 gene regulatory elements: in silico prediction and identification of potential regulatory variants in patients with FSHD.
    Mayes MB; Morgan T; Winston J; Buxton DS; Kamat MA; Smith D; Williams M; Martin RL; Kleinjan DA; Cooper DN; Upadhyaya M; Chuzhanova N
    Hum Genomics; 2015 Oct; 9():25. PubMed ID: 26446085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4.
    Sasaki-Honda M; Jonouchi T; Arai M; Hotta A; Mitsuhashi S; Nishino I; Matsuda R; Sakurai H
    Hum Mol Genet; 2018 Dec; 27(23):4024-4035. PubMed ID: 30107443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.